

Page 2, line 23, please replace "responding" with -respond-

Page 2, line 24, please insert the heading -Summary of The Invention- centered on the line;

Page 2, line 26, please insert a comma before and after "among others";

Page 2, line 36, please replace "binds specifically" with -specifically binds-;

Page 3, line 3, please insert a period after "cytoplasm";

Page 3, line 4, please replace "where it" with -The released toxin irreversibly- , and after "synthesis", delete "irreversibly";

Page 3, line 13, please replace "At" with -ITs have been investigated at-;

Page 3, line 14, please delete "ITs have been investigated";

Page 4, line 2, please replace "has shown to be" with -is-;

Page 4, line 8, please replace ">" with -more than-;

Page 4, line 9, please insert -the- before "partial";

Page 4, line 24, please replace "dosis" with -dose-;

Page 4, line 33, please replace "GvH" with -GVHD-; and insert a comma after "Also";

Page 5, line 2, please delete the period after "art" and insert -and-;

Page 5, line 3, at the beginning of the line, please delete "It";

Page 5, line 4, at the end of the line, please replace "It" with -Typically, the molecule-;

Page 5, line 5, please delete "typically";

Page 5, lines 6-7, please delete "(receptor is defined as any molecule capable of a specific interaction),";

Page 5, line 10, before "Toxic", please insert -Receptor is defined as any molecule capable of a specific interaction.-;

Page 5, line 12, please replace "be it" with -either-;

Page 5, lines 17-18, please replace "Preferred is Ricin A," with -Ricin A is preferred.-

Page 5, line 18, please delete "preferably deglycosylated (";

Page 5, line 21, please delete the closed parenthesis after "preferred" and please insert a comma after "embodiments";

Page 5, line 29, please insert a comma after "above";

Page 5, lines 33, please insert -antibody- before "molecules" , delete the comma after molecules and delete "which are both antibodies";

Page 5, lines 35, please replace "GvH" with -GVHD- and after "occurs," please insert -unlike current treatments,-;

Page 5, lines 36, please delete the comma and insert a period after "corticosteroids";

Page 6, line 6, please insert a period after "manner" and replace "such as by making" with -For example, the coupling can occur-;

Page 6, lines 11-12, please remove the parenthesis around the sentence beginning with "Upon";

Page 6, line 15, please delete "according";

Page 6, line 18, please replace "There is a" with -A-;

Page 6, line 20, please replace "because" with -is that- and after "can", delete "then";

Page 6, line 26, please delete the comma after "cells", replace "also" with -or- and insert and comma after "with";

Page 6, line 27, please insert a comma after "instance";

Page 6, line 33, please insert commas after "invention" and "embodiment";

Page 6, line 34, please insert -, which recognizes CD3,- after "composition";

Page 6, line 35, please delete the comma after "thereof" and delete "which recognizes CD3";

Page 6, line 37, please replace "limitas" with -limits-;

Page 7, line 5, please insert a comma after "deglycosylated" and replace "Ricin" with -ricin-;

Page 7, line 10, please replace "dosis" with -doses- and replace "Ricin" with -ricin-;

Page 7, line 18, please replace "hereinbefore" with -above- and replace "GvHD" with -GVHD- and insert a comma after "rejection";

Page 7, line 26, please delete "according to anyone of claims 1-13";

Page 7, line 30, please delete "usually even";

Page 7, line 30, please replace "Typically" with -In contrast to what prior art regime have accomplished, typically,-;

Page 7, lines 31-2, please insert a period after "time" and delete "in contrast to what prior art regime have accomplished.";

Page 7, line 32, before, exemplified, please replace "The" with -Another advantage of the present invention is that the-;

Page 7, lines 33-4, please insert a period after "NK cells" and delete "which is another

advantage of the present invention.”;

Page 8, line 1, before the heading “Detailed description of the invention”, please insert the following:

-BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a view of an example of an immunotoxin.

FIG. 2 is a view of an example of the mechanism of action of an immunotoxin with an antigen.

FIG. 3 is a view of a SMPT.

FIG. 4 is a bar graph depicting the proliferation of responder cells when SPV-T3a was added following the initiation of a mixed lymphocyte culture. The graph illustrates that alloactivation was blocked when SPV-T3a was added following the initiation of the mixed lymphocyte culture.

FIG. 5 consists of two graphs charting incubation of a CTL-clone treated with SPV-T3a as compared to a control group and IgG2b-mAb. The first graph illustrates the reduction of CTL-cytotoxicity directly following treatment. The second graph shows the reduction of the CTL-cytotoxicity on day 5.

FIG. 6 is a graph illustrating the reduction of NK-activity determined by a ^{51}Cr labeled release incubating with saturating amounts of WT1-dgRTA, IgG2a-dgRTA, WT1 and SPV-T3a-dgRTA.

FIG. 7 consists of a chart and graph illustrating the weight changes following the administration of the IT-cocktail.

FIG. 8 consists of two graphs comparing SPV-T3a-dgRTA, WT1-dgRTA, and IT cocktail at different serum concentrations. Each graph illustrates the rise in serum concentration following infusion.

FIG. 9 consists of two graphs illustrating CK levels after infusion of the IT cocktail. The arrows pointing to the graphs show the times that the IT cocktail was placed in the system. The graphs illustrate a rise of CK-levels following infusion.

FIG. 10 is a graph illustrating the reduction of circulating T cells and NK cells following a first infusion. The graph is based upon a 24 hour scale.

FIG. 11 consists of two pictures of skin biopsies of a patient. Picture A depicts the epidermis

before the IT-cocktail treatment while picture B depicts the epidermis two weeks after the IT-cocktail treatment. Picture A is typical for severe GVHD.

FIG. 12 is a graph depicting the response of lymphocytes in a test subject after the IT cocktail was placed in the system.-;

Page 8, line 1, please replace "Detailed description of the invention" with -DETAILED DESCRIPTION OF THE INVENTION-;

Page 8, line 7, please insert -such- after "reagents" ;

Page 8, line 13, please insert -%- after "73" and insert -%- after "45";

Page 8, line 19, please replace "we" with -RTA was-;

Page 8, line 20, please delete "RTA" and delete the parentheses around "almost"

Page 8, line 23, please delete "have";

Page 8, line 26, please insert a period after "GVHD" and replace "and that this" with -This-;

Page 9, line 16, please replace "change" with -chance-;

Page 9, line 26, please delete "do";

Page 9, line 20, please insert a period after "below";

Page 9, line 33, please delete "and";

Page 9, lines 33-34 , please delete "(page 1, appendix III)";

Page 10, lines 4-5, please delete "(see also page 2, appendix III)";

Page 10, line 9, please insert -such- after "situation";

Page 10, line 13, please replace "why we choose for" with -we selected-;

Page 10, line 14, after "and" please insert a comma followed by -out of the majority of the T cells isolated and examined from the human population, SPV-T3a-;

Page 10, lines 15-16, please insert a period after "release" and delete "T cells isolated out of the majority of the human population examined."

Page 10, line 23, please delete "(see also page 3, appendix III)";

Page 10, lines 26-27, please delete "(see also page 4, appendix III)";

Page 10, line 27, please replace "The significance of this is stressed by our" with -Our-;

Page 10, line 28, please delete the period after "GVHD" and replace "In" with -is that-;

Page 10, line 29, please delete "our view,";

Page 11, line 9, please replace "of its" with -it is an-;

Page 11, line 11, please insert a comma after "Nijmegen";

Page 11, line 22, please insert a comma after "Nijmegen"; and replace "which" with -who-

Page 11, line 25, before "allergic", please insert -either an- and replace "reactions" with -reaction-;

Page 11, line 26, please replace "nor in" with -or-;

Page 11, line 26, please delete "(Dr W Tax, personal communication)";

Page 11, line 35, please replace "is" with -has been-;

Page 12, line 8, please replace the open parenthesis with -which is-;

Page 12, line 9, please delete the comma and insert a period after "toxicity" and replace "see" with -(See-;

Page 12, line 12, please delete the open parenthesis;

Page 12, line 13, please delete the closed parenthesis;

Page 12, line 19, please replace "trail" with -trial-;

Page 12, line 21, please insert a period after "(50)";

Page 12, line 28, please delete the comma after "RTA";

Page 13, line 10, please insert a period after "IgG-dgRTA";

Page 13, line 11, please replace "which" with -The MTD- and after "life" insert -of-;

Page 13, line 12, please remove both parenthesis;

Page 13, line 15, please replace ">" with -greater than-;

Page 13, line 24, please replace "relative" with -relatively-;

Page 13, line 25, please replace the "~" with -about-;

Page 13, line 26, please insert a period after "infusions";

Page 14, line 2, please replace "2nd-line" with -second line-;

Page 15, line 20, please delete "(Appendix V)";

Page 15, line 22, please replace "syndrom" with -syndrome-;

Page 15, line 23, please replace "being" with -are-;

Page 16, line 5, please change "observered" to --observed--;

Page 16, line 14, please change "non" to --none--;

Page 16, line 29, please insert a comma after "study";

Page 16, line 34, please change "billirubin" to --bilirubin--;

Page 17, line 2, please insert --and-- before "thrombocytes";

Page 17, line 11, please change "examination" to --examinations-- and change "is" to --are--;

Page 17, line 13, please insert a comma after "dose";

Page 17, line 16, please insert -- Blood is analyzed-- before "Every" and change "billirubin" to --bilirubin--;

Page 17, line 18, please delete "(see Appendix I)";

Page 17, line 20, please change "frequention" to --frequentation--;

Page 17, line 22, please insert a comma after "infusion";

Page 17, line 23, please change "Besides" to --In addition--;

Page 17, line 25, please insert a comma after "dose";

Page 17, line 32, please insert a comma after "results", change "half lifes" to --half-lives--,
and change "is" to --are--;

Page 18, line 14, please change "monocyte" to --monocytes--;

Page 18, line 17, please change "proliverative" to --proliferative--;

Page 18, line 24, please insert a comma after "dose";

Page 18, line 25, please change "staged" to --evaluated--;

Page 18, line 27, please delete "(Appendix II)";

Page 18, line 31, please delete "(see Appendix II)"

Page 19, line 15, please change "appendix" to --Appendix--;

Page 19, line 24, please insert --The-- before "Monoclonal";

Page 19, line 28, please change "affinitychromatography" to --affinity chromatography--;

Page 19, line 15, please change "manufacturers" to --manufacturer's--;

Page 19, line 15, please replace "in appendix III" with -herein-;

Page 19, line 18-19, please replace "in Appendix IV" with -herein-;

Page 20, line 11, please insert a comma after the second occurrence of "Ghetie";

Page 20, line 12, please insert a period after "V" and insert a comma after "al.";

Page 20, lines 12-13, please italicize "The GLP large scale preparation of immunotoxins
containing degycosylated ricin A chain and a hindered disulfide bond";

Page 28, line 1, please replace "Appendix I" with -Table 2-;